INO — Inovio Pharmaceuticals Balance Sheet
0.000.00%
- $70.41m
- -$23.70m
- $0.22m
Annual balance sheet for Inovio Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 412 | 401 | 253 | 145 | 94.1 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 19.1 | 8.03 | 11.7 | 2.41 | 1.2 |
Prepaid Expenses | |||||
Total Current Assets | 471 | 448 | 315 | 153 | 97.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 24.1 | 29 | 18 | 14.5 | 11.8 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 540 | 496 | 349 | 171 | 113 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 41.7 | 65.7 | 96.9 | 42.6 | 35.3 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 78.6 | 96.3 | 126 | 53.6 | 44.7 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 461 | 400 | 222 | 117 | 68.5 |
Total Liabilities & Shareholders' Equity | 540 | 496 | 349 | 171 | 113 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |